Recro Pharma, Inc. (REPH) to Release Quarterly Earnings on Wednesday
Recro Pharma, Inc. (NASDAQ:REPH) will be issuing its quarterly earnings data on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter.
Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.06. Recro Pharma had a negative net margin of 46.75% and a negative return on equity of 56.04%. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.90 million. On average, analysts expect Recro Pharma to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of Recro Pharma, Inc. (REPH) opened at $8.75 on Tuesday. Recro Pharma, Inc. has a 1-year low of $5.81 and a 1-year high of $10.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.81 and a quick ratio of 5.23.
An institutional investor recently bought a new position in Recro Pharma stock. California State Teachers Retirement System acquired a new stake in shares of Recro Pharma, Inc. (NASDAQ:REPH) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 24,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $169,000. California State Teachers Retirement System owned 0.13% of Recro Pharma at the end of the most recent quarter. 65.25% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have issued reports on REPH. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Piper Jaffray Companies set a $11.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Tuesday, July 25th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $12.63.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.